Kiniksa Pharmaceuticals International, plc

Thank you for standing by and welcome to the Connexa Pharmaceuticals Second Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 11 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Jonathan Kirshenbaum, Investor Relations. Please go ahead, sir.

Thank you, operator. Good morning, everyone, and welcome to the Canixa Pharmaceuticals second quarter 2026 earnings call. A press release highlighting our financial results and recent portfolio execution can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction that will be followed by Ross Moat, our Chief Operating Officer, who will provide an update on Arculus commercial execution. From there, Connexa's Chief Medical Officer, Dr. John Paolini, will review our KPL387 development program and the ongoing Phase 2-3 clinical trial in recurrent pericarditis. After that, Mark Ragosa, our Chief Financial Officer, will review our second quarter 2026 financial results. And finally, Sanj will share closing remarks and kick off the Q&A session. Before getting started, Please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings. These statements speak only as the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I'll turn it over to Sanj.

Thanks, Jonathan, and good morning or good afternoon, everyone. Connexa is in a strong position more than halfway through 2026 as we continue to execute across our portfolio. We continue to make excellent progress with ARTLIST and have advanced the KPL 307 program into the pivotal stage with the initiation of the phase three trial, which we have named PASTORAL. Additionally, KPL1161, which is our FC-modified IL-1 alpha and beta inhibitor with a target profile of causally dosing, is progressing well, and the program remains on track to initiate a phase one study by the end of this year. Importantly, we've continued to maintain a robust financial position, which together with strong commercial momentum and key advancements in our development pipeline positions the company with multiple value creating drivers in both the near and long-term. Our ongoing execution of the Onculus commercial strategy resulted in a meaningful increase in the number of patients on therapy. Robust revenue growth of more than $29 million over the previous quarter draw sales of $243.6 million in the second quarter. And we continue to build on our strong commercial momentum, and we've raised our full year 2026 revenue guidance from $930 to $945 million to between $980 and $995 million. On the clinical side, just this morning, we announced data from the dose-focusing portion of the KPL387 Phase 2, Phase 3 study in recurrent pericarditis. On the basis of the Phase 2 data, I'm happy to report that we are moving forward with the target profile of a monthly dose into the pivotal Phase 3 portion of the trial. Today, we also announced that this Phase 3 study has already started and is now enrolling and dosing patients. The ongoing Phase 3 study, Passerall, marks a key milestone in bringing additional treatment options to patients suffering from recurrent pericarditis. This trial follows Rapsody, the successful Phase 3 program with Arclist, with both trials having the same registrational endpoint of reduction in the risk of pericarditis recurrence. John will share additional details about the phase two data in a moment, as well as provide an overview of the design of this phase three study. We anticipate a potential commercial launch of KPL 307 in the 2028 and 2029 timeframe. Extending our leadership in the recurrent pericarditis market so we can help many more patients. And with that, I'll turn it over to Ross to review our commercial execution. Ross.